Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism - PubMed (original) (raw)
Randomized Controlled Trial
Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism
Z Merza et al. Int J Androl. 2006 Jun.
Abstract
Clinical studies suggest there may be a threshold concentration of serum testosterone below which replacement will result in skeletal and psychological benefit. We evaluated the response to testosterone in men with borderline hypogonadism. A randomized double-blind placebo-controlled trial in 39 men over age 40 years presenting with sexual dysfunction and a borderline low testosterone level (total testosterone <10 nmol/L or free androgen index <30%). Patients were randomized to Testoderm TTS body patch (5 mg/day, n = 20) or a placebo patch (n = 19) for 6 months, followed by open-label testosterone replacement for a further 6 months in all patients. During the placebo-controlled phase of the study serum testosterone increased significantly on testosterone vs. placebo treatment (p = 0.004); this was associated with a decrease in total body fat mass (p = 0.019) and increase in haemoglobin level (p = 0.036). There were no significant changes in lean body mass, markers of bone turnover, and measures of bone mineral density (BMD). There was evidence of difference in quality of life according to the Male Erectile Dysfunction Quality of Life questionnaire (MEDQoL score, p = 0.017), mainly accounted for by deterioration in the placebo arm. When the active treatment period was combined for placebo and testosterone groups, the within-patient analysis showed a significant effect of testosterone to decrease markers of bone resorption (uNTX/Cr, p = 0.007; iFDPD/Cr, p = 0.0006) and to increase lean body mass (p = 0.001). There was little convincing evidence from this study that testosterone replacement is likely to have major benefit in men over age 40 years with borderline hypogonadism and sexual dysfunction. However, there was evidence of suppression in bone resorption and hence longer and larger studies are needed to examine its effect on BMD.
Similar articles
- Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels.
Uebelhart B, Herrmann F, Pavo I, Draper MW, Rizzoli R. Uebelhart B, et al. J Bone Miner Res. 2004 Sep;19(9):1518-24. doi: 10.1359/JBMR.040503. Epub 2004 May 3. J Bone Miner Res. 2004. PMID: 15312253 Clinical Trial. - Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, Louis ED, Mulligan T, Foster PS, Shenal BV, Armaghani SJ, Jacobson C, Wu S, Crucian G. Okun MS, et al. Arch Neurol. 2006 May;63(5):729-35. doi: 10.1001/archneur.63.5.729. Arch Neurol. 2006. PMID: 16682542 Clinical Trial. - DHEA in elderly women and DHEA or testosterone in elderly men.
Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ 3rd, Smith GE, Khosla S, Jensen MD. Nair KS, et al. N Engl J Med. 2006 Oct 19;355(16):1647-59. doi: 10.1056/NEJMoa054629. N Engl J Med. 2006. PMID: 17050889 Clinical Trial. - [Should older men be treated with testosterone?].
Svartberg J. Svartberg J. Tidsskr Nor Laegeforen. 2005 Apr 7;125(7):879-82. Tidsskr Nor Laegeforen. 2005. PMID: 15815734 Review. Norwegian. - Testosterone in older men after the Institute of Medicine Report: where do we go from here?
Harman SM. Harman SM. Climacteric. 2005 Jun;8(2):124-35. doi: 10.1080/13697130500118001. Climacteric. 2005. PMID: 16096168 Review.
Cited by
- Benefits and Consequences of Testosterone Replacement Therapy: A Review.
As P, Nn T, Ka O, Jc H. As P, et al. Eur Endocrinol. 2013 Mar;9(1):59-64. doi: 10.17925/EE.2013.09.01.59. Epub 2013 Mar 15. Eur Endocrinol. 2013. PMID: 30349612 Free PMC article. Review. - Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy.
Surampudi PN, Wang C, Swerdloff R. Surampudi PN, et al. Int J Endocrinol. 2012;2012:625434. doi: 10.1155/2012/625434. Epub 2012 Mar 14. Int J Endocrinol. 2012. PMID: 22505891 Free PMC article. - Testosterone replacement in men with sexual dysfunction.
Lee H, Hwang EC, Oh CK, Lee S, Yu HS, Lim JS, Kim HW, Walsh T, Kim MH, Jung JH, Dahm P. Lee H, et al. Cochrane Database Syst Rev. 2024 Jan 15;1(1):CD013071. doi: 10.1002/14651858.CD013071.pub2. Cochrane Database Syst Rev. 2024. PMID: 38224135 Free PMC article. Review. - Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology.
Isidori AM, Balercia G, Calogero AE, Corona G, Ferlin A, Francavilla S, Santi D, Maggi M. Isidori AM, et al. J Endocrinol Invest. 2015 Jan;38(1):103-12. doi: 10.1007/s40618-014-0155-9. Epub 2014 Nov 11. J Endocrinol Invest. 2015. PMID: 25384570 Free PMC article. Review. - Treatment of Men for "Low Testosterone": A Systematic Review.
Huo S, Scialli AR, McGarvey S, Hill E, Tügertimur B, Hogenmiller A, Hirsch AI, Fugh-Berman A. Huo S, et al. PLoS One. 2016 Sep 21;11(9):e0162480. doi: 10.1371/journal.pone.0162480. eCollection 2016. PLoS One. 2016. PMID: 27655114 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources